keyword
MENU ▼
Read by QxMD icon Read
search

Long acting antipsychotics

keyword
https://www.readbyqxmd.com/read/29039277/is-paliperidone-palmitate-more-effective-than-other-long-acting-injectable-antipsychotics
#1
R Patel, E Chesney, M Taylor, D Taylor, P McGuire
BACKGROUND: Paliperidone palmitate is one of the most widely prescribed long-acting injectable (LAI) antipsychotics in the UK. However, it is relatively expensive and there are few data comparing its effectiveness to that of other LAI antipsychotics. We sought to address this issue by analyzing a large anonymized electronic health record (EHR) dataset from patients treated with LAI antipsychotics. METHODS: EHR data were obtained from 1281 patients in the South London and Maudsley NHS Foundation Trust (SLaM) who started treatment with a LAI antipsychotic between 1 April 2011 and 31 January 2015...
October 17, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/29039241/aripiprazole-long-acting-injection-a-mirror-image-study-of-its-effects-on-hospitalisation-at-one-year
#2
David M Taylor, Anna Sparshatt, Fahima Amin, Ian Osborne, Olubanke Dzahini, Gwenllian Hughes, Catrin Fischetti
Second generation antipsychotic long-acting injections have a greater cost than older depots. Their cost-effectiveness has yet to be established. We conducted a non-interventional, observational, follow-up of patients prescribed aripiprazole long-acting injection in two centres using a mirror image method. Data were available for 160 patients consecutively prescribed aripiprazole long-acting injection, of whom 30 were not included in the analysis (21 forensic patients, five incomplete data and four lost to follow-up)...
October 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29018549/perceptions-and-knowledge-of-antipsychotics-among-mental-health-professionals-and-patients
#3
Lindah Cahling, Anders Berntsson, Gabriella Bröms, Lars Öhrmalm
Aims and method To assess the patients' most influential concerns regarding long-acting injectable antipsychotics (LAIs) and mental health professionals' preconceptions about these concerns. For both groups, to assess the level of knowledge about LAIs. This cross-sectional study used semi-structured interviews of patients with schizophrenia or schizoaffective disorder (n = 164), nurses (n = 43) and physicians (n = 20). Results The mental health professionals overestimated many of the patients' fears of LAIs, and the expressed fears exceeded the actual experiences of patients already on LAIs...
October 2017: BJPsych Bulletin
https://www.readbyqxmd.com/read/29017344/book-review-antipsychotic-long-acting-injections-antipsychotic-long-acting-injections-2nd-ed-haddad-p-lambert-t-lauriello-j-eds-oxford-oxford-university-press-2016-366pp-isbn-978-0-19-872947-1
#4
Phillip O'Rourke
No abstract text is available yet for this article.
April 2017: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/28962597/periodic-catatonia-with-long-term-treatment-a-case-report
#5
Ruei-An Chen, Tiao-Lai Huang
BACKGROUND: Periodic catatonia has long been a challenging diagnosis and there are no absolute guidelines for treatment when precipitating factors are also unclear. We report a schizophrenia patient with periodic catatonia with a 15-year treatment course. A possible correlation between decreased daylight exposure and periodic attacks has been observed. CASE PRESENTATION: We describe a 49-year-old woman with periodic catatonia associated with schizophrenia with 15 years of follow-up...
September 29, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28953846/does-risperidone-long-acting-injectable-depot-rlai-reduce-number-of-admissions-to-hospital
#6
Hellme Najim, Ashish Pathak, Andrea Pathak
BACKGROUND: Adherence to treatment is a major issue in relapse prevention in schizophrenia. Injectable depot has been claimed to improve non-adherence. A study in the North of England has shown that risperidone long acting injectable form has reduced number of admissions and number of days stayed in hospital. Our study aimed to replicate the previous study in the South of England. METHODS: A retrospective study was conducted in the South Essex Foundation University NHS trust...
September 2017: Psychiatria Danubina
https://www.readbyqxmd.com/read/28953789/benzodiazepines-as-adjunctive-therapy-in-treatment-refractory-symptoms-of-schizophrenia
#7
Joanna Szarmach, Adam Włodarczyk, Wiesław Jerzy Cubała, Mariusz Stanisław Wiglusz
Antipsychotics are a key intervention strategy in pharmacotherapy in schizophrenia. However, the benzodiazepines are often prescribed to control sleep disturbances, anxiety or hostile behaviour. There is some evidence supporting the combination therapy with antipsychotics and benzodiazepines providing beneficiary treatment effect to the psychosis in positive and negative symptom domains as well as catatonia or adverse reactions to antipsychotic drugs. In particular, in a population suffering from residual symptoms of schizophrenia, in particular anxiety, emotional flattening, being refractory to approved treatment strategies, benzodiazepines as add-on to antipsychotics seem to be an option...
September 2017: Psychiatria Danubina
https://www.readbyqxmd.com/read/28953786/oral-versus-long-acting-injectable-antipsychotics-hospitalisation-rate-of-psychotic-patients-discharged-from-an-italian-psychiatric-unit
#8
Vincenzo Sicilia, Valentina Del Bello, Norma Verdolini, Alfonso Tortorella, Patrizia Moretti
OBJECTIVE: The primary aim is to verify the efficacy of long-acting injectable (LAI) and oral antipsychotics (AP) in terms of re-hospitalisation rate of patients with psychotic disorders. The second aim is to evaluate socio-demographic and clinical differences in patients that were re-hospitalised after the index discharge compared to patients that were not re-hospitalised. Finally, socio-demographic and clinical differences of re-hospitalised patients that were prescribed at discharge with oral or LAI AP were analysed...
September 2017: Psychiatria Danubina
https://www.readbyqxmd.com/read/28930768/a-6-month-prospective-trial-of-a-personalized-behavioral-intervention-long-acting-injectable-antipsychotic-in-individuals-with-schizophrenia-at-risk-of-treatment-nonadherence-and-homelessness
#9
Martha Sajatovic, Luis F Ramirez, Edna Fuentes-Casiano, Jamie Cage, Curtis Tatsuoka, Michelle E Aebi, Ashley Bukach, Kristin A Cassidy, Jennifer B Levin
PURPOSE: Long-acting injectable antipsychotics (LAI) can optimize adherence for high-risk serious mental illness (SMI). This customized adherence-enhancement approach delivered by social worker interventionists was combined with LAI (CAE-L) of paliperidone palmitate for homeless, poorly adherent individuals with SMI. METHODS: This 6-month prospective, uncontrolled trial of CAE-L in 30 recently homeless individuals with SMI assessed adherence using the Tablets Routine Questionnaire, injection frequency, and SMI symptoms measured by the Positive and Negative Syndrome Scale, Brief Psychiatric Rating Scale, and Clinical Global Impressions...
September 19, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28919757/once-monthly-paliperidone-palmitate-in-early-stage-schizophrenia-a-retrospective-non-interventional-1-year-study-of-patients-with-newly-diagnosed-schizophrenia
#10
Robin Emsley, Ludger Hargarter, Paul Bergmans, Boran Uglešić, Abdullah Cem Sengül, Antonino Petralia, Angelina Khannanova, Pierre Cherubin, Andreas Schreiner
BACKGROUND: Long-acting antipsychotic therapy may be best suited for patients in the early stage of schizophrenia, when the most can be done before disease progression associated with poor adherence occurs. We explored the patterns of use of once-monthly paliperidone palmitate (PP1M), concomitant medication use, hospitalization, and clinical outcomes of adult, newly diagnosed patients with schizophrenia receiving continuous treatment with PP1M for at least 12 months. METHODS: This was an international, multicenter, exploratory, retrospective chart review of medical records of adult patients who were newly diagnosed (not more than 1 year before initiation of PP1M treatment) with schizophrenia and who had received continuous treatment with PP1M for ≥12 months in naturalistic clinical settings...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28919292/treatment-patterns-health-care-resource-utilization-and-spending-in-medicaid-beneficiaries-initiating-second-generation-long-acting-injectable-agents-versus-oral-atypical-antipsychotics
#11
Dominic Pilon, Neeta Tandon, Marie-Hélène Lafeuille, Rhiannon Kamstra, Bruno Emond, Patrick Lefebvre, Kruti Joshi
PURPOSE: Second-generation long-acting injectable therapies (SGA-LAIs) may reduce health care resource utilization (HRU) and health care costs compared with daily oral atypical antipsychotics (OAAs) in patients with schizophrenia due to reduced dosing frequency, delivery/monitoring by a health care provider, and improved adherence. The aim of the present study was to compare treatment patterns, HRU, and Medicaid spending in patients with schizophrenia initiated on SGA-LAIs (overall and according to agent) versus OAAs...
September 14, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28895766/adherence-persistence-and-inpatient-utilization-among-adult-schizophrenia-patients-using-once-monthly-versus-twice-monthly-long-acting-atypical-antipsychotics
#12
Dominic Pilon, Matthew Alcusky, Yongling Xiao, Philippe Thompson-Leduc, Marie-Hélène Lafeuille, Patrick Lefebvre, Carmela Benson
AIMS: This study compared healthcare resource utilization (HRU), healthcare costs, adherence, and persistence among adult patients with schizophrenia using once-monthly (OM) vs twice-monthly (TM) atypical long-acting injectable (LAI) antipsychotic (AP) therapy. MATERIALS AND METHODS: A longitudinal retrospective cohort study was conducted using Medicaid claims data from six states. Patients initiated on aripiprazole or paliperidone palmitate were assigned to the OM cohort; risperidone-treated patients were assigned to the TM cohort...
October 12, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28895758/medication-adherence-and-discontinuation-of-long-acting-injectable-versus-oral-antipsychotics-in-patients-with-schizophrenia-or-bipolar-disorder
#13
Mallik Greene, Jessie Tingjian Yan, Eunice Chang, Ann Hartry, Maëlys Touya, Michael S Broder
AIMS: To examine medication adherence and discontinuation in two separate groups of patients with schizophrenia or bipolar disorder (BD), who began receiving a long-acting injectable antipsychotic (LAI) versus those who changed to a different oral antipsychotic monotherapy. MATERIALS AND METHODS: The Truven Health Analytics MarketScan Multi-State Medicaid claims database was used to identify patients with schizophrenia; Truven Health Analytics MarketScan Commercial and Medicaid claims databases were used to identify patients with BD...
September 12, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28869705/long-acting-injectable-antipsychotics-for-prevention-and-management-of-violent-behaviour-in-psychotic-patients
#14
REVIEW
Pavel Mohr, Pavel Knytl, Veronika Voráčková, Anna Bravermanová, Tomáš Melicher
BACKGROUND AND AIMS: It has been well established that long-term antipsychotic treatment prevents relapse, lowers number of rehospitalisations, and also effectively reduces violent behaviour. Although violent behaviour is not a typical manifestation of schizophrenia or other psychotic disorders, the diagnosis of psychosis increases the overall risk of violence. One of the few modifiable factors of violence risk is adherence with medication. In contrast, non-adherence with drug treatment and subsequent relapse increases risk of violent acts...
September 4, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28851326/dilemma-of-treating-schizophrenia-during-pregnancy-a-case-series-and-a-review-of-literature
#15
Andreea Teodorescu, Petru Ifteni, Marius Alexandru Moga, Victoria Burtea, Nicusor Bigiu
BACKGROUND: The choice of antipsychotic treatment during pregnancy remains controversial, mainly due to a lack of exposure and outcome data. Randomized clinical trials are practically impossible due to ethical reasons. Our reports describe three cases of closely monitored female patients with schizophrenia who were treated with olanzapine during pregnancy. The novelty of reports is that all patients were previously treated with olanzapine long acting injectable (LAI) for an average period of 3...
August 29, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28843143/effects-of-oral-versus-long-acting-antipsychotics-on-social-functioning-a-psychiatrists-survey-in-india
#16
Prasad Rao Gundugurti, Rajesh Nagpal, Ashit Sheth, Prashant Narang, Sonal Gawande, Vikram Singh
BACKGROUND: Schizophrenia is associated with functional challenges for patients; relapses in schizophrenia may lead to increased treatment costs and poor quality of life. OBJECTIVE: This SUSTAIN-I study was conducted to establish psychiatrists' perspective on impact of long-acting injectables (LAIs) antipsychotics on the socio-economic and functional burden of schizophrenia. METHODS: This cross-sectional, survey-based study was conducted in 5 cities in India...
August 9, 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/28839338/metabolic-and-endocrine-profiles-during-1-year-treatment-of-outpatients-with-schizophrenia-with-aripiprazole-lauroxil
#17
Henry A Nasrallah, Ralph Aquila, Arielle D Stanford, Hasan H Jamal, Peter J Weiden, Robert Risinger
BACKGROUND: We assessed long-term metabolic and endocrine profiles of outpatients with schizophrenia participating in a one-year open-label extension study of monthly aripiprazole lauroxil (AL), a long-acting injectable antipsychotic. METHODS: Patients (N = 478) were enrolled in a 52-week, open-label extension study of AL monotherapy administered by intramuscular injection every 4 weeks. Of these, most (368) received AL 882 mg and the remainder AL 441 mg as their fixed-dose regimen...
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28832262/long-acting-injectable-antipsychotics-update-lengthening-the-dosing-interval-and-expanding-the-diagnostic-indications
#18
Leslie Citrome
Long-acting injectable (LAI) antipsychotics are a useful but underutilized option in the management of schizophrenia. Areas covered: This is a narrative review of newer LAI antipsychotics approved by the US Food and Drug Administration and is an update to a previously published review from 2013. Emphasized are new indications and new dosing intervals. Expert commentary: Ensuring that persons receiving oral antipsychotics are aware that LAI antipsychotics are available is important. The use of LAI antipsychotics can decrease the risk of relapse in both first-episode and chronic schizophrenia...
September 4, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28828976/brexpiprazole-a-partial-dopamine-agonist-for-the-treatment-of-schizophrenia
#19
Asli Ekinci, Okan Ekinci
BACKGROUND: Schizophrenia is a chronic and debilitating mental disorder that affects the patient's and their family's life. The disease remains a complicated disorder that is challenging to treat, despite there being a large antipsychotic armamentarium. Brexpiprazole acts both as a partial agonist at the serotonin 5-HT1A and dopamine D2 receptors and as an antagonist at the serotonin 5-HT2A and noradrenaline alpha1B and alpha2C receptors, all with similar potency. This balanced receptor profile may produce promising antipsychotic effects on positive, negative and cognitive symptoms in schizophrenia with minimal adverse effects...
August 20, 2017: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/28816923/evaluation-of-concurrent-oral-and-long-acting-injectable-antipsychotic-prescribing-at-the-minneapolis-veterans-affairs-health-care-system
#20
Erica Dimitropoulos, Lisa Drogemuller, Kara Wong
BACKGROUND: Antipsychotic polypharmacy is defined as the concomitant prescribing of more than 1 antipsychotic medication for an individual patient. Despite clinical guideline recommendations, long-acting injectable antipsychotics (LAIAs) are often used together with oral antipsychotics (OAPs) to treat a variety of psychiatric illnesses. Little research exists to address this form of antipsychotic polypharmacy, and its role in therapy is poorly understood. The purpose of this evaluation was to determine the prevalence of this prescribing pattern at our facility, identify provider rationale for polypharmacy, and analyze trends...
August 15, 2017: Journal of Clinical Psychopharmacology
keyword
keyword
81198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"